Evidence map›Paper›PMID 40794265›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025

In vitro activity of the novel β-lactamase inhibitor FL058 combined with meropenem against KPC- or NDM-producing enterobacterales and Pseudomonas aeruginosa.

Feng Yang, Yang Yang, Shi Wu, Chengkang Tang, Dandan Yin, Yan Guo, Demei Zhu, Fupin Hu

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Feng Yang *Institute of Antibiotics, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, 200040, China.
Yang Yang *Institute of Antibiotics, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, 200040, China.
Shi WuInstitute of Antibiotics, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, 200040, China.
Chengkang TangInstitute of Antibiotics, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, 200040, China.
Dandan YinInstitute of Antibiotics, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, 200040, China.
Yan GuoInstitute of Antibiotics, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, 200040, China. guoyan@fudan.edu.cn.
Demei ZhuInstitute of Antibiotics, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, 200040, China.
Fupin HuInstitute of Antibiotics, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, 200040, China. hufupin@fudan.edu.cn.ORCID http://orcid.org/0000-0002-4493-0619

Funding

China Antimicrobial Surveillance Network Independent Medical Grants from Pfizer, 2020QD049Shanghai Antimicrobial Surveillance Network 3030231003Shanghai Municipal Health Commission 20244Y0152Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai GWVI-3
6 · The paper itself

Abstract

purposeCarbapenem-resistant organisms pose a significant public health threat due to high mortality and limited treatment options. This study aimed to evaluate the in vitro antimicrobial activity of the novel β-lactamase inhibitor FL058 combined with meropenem against carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa clinical isolates.

methodsThe MICs of 85 clinical isolates, including KPC- or NDM-producing Enterobacterales and carbapenem-resistant/susceptible P. aeruginosa, were determined using broth microdilution. Additionally, bactericidal activity, effects of culture conditions, post-antibiotic effect, and post-β-lactamase inhibitory effect of meropenem-FL058 were evaluated. Ceftazidime-avibactam served as comparator.

resultsMeropenem-FL058 showed potent activity against KPC-producing Enterobacterales (100% susceptibility, MIC

conclusionMeropenem-FL058 showed promising in vitro activity against KPC-producing Enterobacterales and some NDM-1/5-producing strains. However, its limited efficacy against certain NDM-producers and carbapenem-resistant P. aeruginosa highlights the variability in activity across different resistance mechanisms, suggesting the potential need for combination strategies in clinical settings.

Indexed as

Anti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-LactamasesEnterobacteriaceaeMeropenemPseudomonas aeruginosaCarbapenem-Resistant EnterobacteriaceaeEnterobacteriaceae InfectionsHumansMicrobial Sensitivity TestsPseudomonas InfectionsAnti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-lactamase NDM-1beta-LactamasesMeropenemAntimicrobial susceptibility testingEnterobacteralesFL058MeropenemPseudomonas aeruginosa

Identifiers

PMID40794265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.